Premium
RESPONSE TO BRENTUXIMAB VEDOTIN BY CD30 EXPRESSION: RESULTS FROM FIVE TRIALS IN PTCL, CTCL, AND B‐CELL LYMPHOMAS
Author(s) -
Jagadeesh D.,
Horwitz S.,
Bartlett N.L.,
Advani R.,
Jacobsen E.,
Duvic M.,
Gautman A.,
Rao S.,
Onsum M.,
Fanale M.,
Kim Y.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.149_2631
Subject(s) - brentuximab vedotin , cd30 , mycosis fungoides , medicine , lymphoma , anaplastic large cell lymphoma , oncology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom